SCHEMBL4969753

SCHEMBL4969753

O=C(O)C#CCCCCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.57
HMGCR P04035 3/20 0.57
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TSHR P16473 1/20 0.50
NFKB1 P19838 1/20 0.50
PMP22 Q01453 1/20 0.50
RECQL P46063 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31520021 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520016 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520020 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520019 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL30966140 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL28584660 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520015 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520018 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL31520017 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2
SCHEMBL29242822 0.98 PTPN7 (0.61) PTPN7HMGCRLMNAMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4183391-A1 PHARMACEUTICAL COMPOSITION AND USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-05-24 EP claimed
US-20180263991-A1 COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD (CN) 2018-09-20 US claimed
CN-122011115-A Cyclic antibacterial peptide derivative and application thereof 中国人民解放军军事科学院军事医学研究院 2026-05-12 CN disclosed
US-20250326720-A1 CAREBASTINE SALT AND USE OF SAME CHENGDU SHIBEIKANG BIOMEDICAL TECH CO LTD (CN) 2025-10-23 US disclosed
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-08-19 US disclosed
CN-119912668-A Synthesis of linear aliphatic polyesters 丰益国际有限公司 2025-05-02 CN disclosed
EP-4520752-A1 CAREBASTINE SALT AND USE THEREOF Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) 2025-03-12 EP disclosed
CN-118831183-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-10-25 CN disclosed
CN-118265536-A Engineered antibacterial peptides and uses thereof 肽逻辑公司 2024-06-28 CN disclosed
CN-111936502-B Heterobicyclic carboxylic acids and salts thereof 深圳市原力生命科学有限公司 2024-05-31 CN disclosed
CN-118103078-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-05-28 CN disclosed
CN-112312896-A Dosage forms comprising a living biotherapeutic product 4D制药研究有限公司 2021-02-02 CN disclosed
EP-3253751-B1 COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO LTD (CN) 2020-12-09 EP disclosed
EP-3747866-A1 BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2020-12-09 EP disclosed
US-20200121690-A1 SALT OF SUBSTITUTED UREA DERIVATIVE AND USE THEREOF IN MEDICINE NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) 2020-04-23 US disclosed
CN-110582507-A Engineered antimicrobial amphiphilic peptides and methods of use 肽逻辑公司 2019-12-17 CN disclosed
US-10098889-B2 Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-10-16 US disclosed
US-20180263991-A1 COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD (CN) 2018-09-20 US disclosed
EP-0980016-B1 ALIGNING AGENT FOR LIQUID CRYSTAL NISSAN CHEMICAL IND LTD (JP) 2008-09-24 EP disclosed
EP-0980016-A1 ALIGNING AGENT FOR LIQUID CRYSTAL Nissan Chemical Industries, Ltd. (JP) 2000-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200121690-A1 SALT OF SUBSTITUTED UREA DERIVATIVE AND USE THEREOF IN MEDICINE JAK1, SLC14A1, REN PTPN7 96/4885HMGCR 3406/4885LMNA 4446/4885
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A PTPN7 1672/4885HMGCR 4148/4885LMNA 2434/4885
US-20180263991-A1 COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS TPMT, SLC10A1, HPRT1 PTPN7 901/4885HMGCR 36/4885LMNA 1560/4885
US-20250326720-A1 CAREBASTINE SALT AND USE OF SAME HRH4, SLC7A1, HRH1 PTPN7 4173/4885HMGCR 902/4885LMNA 4624/4885
US-10098889-B2 Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals TPMT, SLC10A1, HPRT1 PTPN7 901/4885HMGCR 36/4885LMNA 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.